

## Accreditation and Designation Statements and Disclosure Report

UMDF Mitochondrial Medicine 2024

### **Live Activity:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of *16.00 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of *13.50 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Live activity dates: June 26-29, 2024

Enduring activity dates: October 28, 2024 – October 28, 2027

**The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:**

| Full Legal Name       | Commercial Interest                      | Role   | Level of participation in the activity |
|-----------------------|--|--|--|
| Carlos T. Moraes      | Precision Biosciences                    | Consulting   | Speaker                                |
| Rebecca Dena Ganetzky | Minovia therapeutics<br>Nurture genomics | Consultant<br>Consultant                               | Speaker                                |
| Mark Tarnopolsky      | Exerkine/Stayabove Nutrition             | CEO  | Speaker                                |
| Hilary Vernon         | VectivBioAG<br>ClearviewConsulting       | Research Support<br>Consultant                         | Speaker                                |
| Hilary Vernon         | Stealth Biotherapeutics                  | Clinical trial and research support                    | Speaker                                |
| Richard S. Finkel     | Biogen                                   | Research funding, Advisor<br>Research funding, Advisor | Speaker                                |

|   |   |   |                  |
|---|---|---|------------------|
|   | Scholar Rock                              |   |                  |
|   | Novartis                                  | Research funding, Advisor               |                  |
|   | Astellas                                  | Advisor                                 |                  |
|   | Roche/Genentech                           | Funding, Speaker                        |                  |
|   | Sarepta                                   | Research funding, Advisor               |                  |
|   | Ionis                                     | DSMB member                             |                  |
|   | Dyne                                      | Research funding, Advisor               |                  |
|   | La Jolla Labs                             | Researcher                              |                  |
|   | n-Lorem Fdn                               | Advisor, DSMB member                    |                  |
| David Robinson Lynch                    | PTC                                       | Grant for clinical trial                | Speaker          |
|   | Reata/Biogen                              | Grant for clinical trial                |                  |
|   | Stealth                                   | Grant                                   |                  |
|   | Design                                    | Grant                                   |                  |
|   | Mantle                                    | Grant                                   |                  |
| David Arthur Hadley<br>Whiteman         | Takeda Development<br>Center Americas Inc | Former Employee,<br>Retired Jan 4, 2024 | Speaker          |
|   | Takeda Pharmaceutical<br>Co Ltd           | Stockholder                             |                  |
| Fernando Scaglia                        | UCB                                       | Consultant                              | Planner-Reviewer |
|   | Acer Therapeutics                         | Consultant                              |                  |
|   | Precision BioSciences                     | Consultant                              |                  |
|   | Tisento Therapeutics                      | Consultant                              |                  |
| Anu Elina<br>Suomalainen<br>Wartiovaara | Khondrion                                 | SAB member                              | Speaker          |

|                |                      |   |         |
|----------------|----------------------|---|---------|
|                | NADMED Ltd           | Founder, board member, share owner  |         |
| Linda P Lowes  | Sarepta Therapeutics | I provide training to clinical trial sites and Nationwide Children's Hospital receives support for my salary. I have also received travel support to conferences to present data. | Speaker |
|                | ATOM International   | I am a member of this international training company. Through this company I provide services to several pharmaceutical companies. training company                               |         |
| Shamima Rahman | Reneo                | Virtual SAB member  | Speaker |
|                | Pretzel              | Speaker and Consultant  |         |
|                | Khondrion            | SAB member  |         |
|                | PTC Biotherapeutics  | Virtual SAB member; UK Chief Investigator MIT-E clinical trial  |         |
|                | UCB                  | Consultant; Attendance at meeting on TK2d, Madrid, Spain  |         |
|                | Market Modelers      | Consultant  |         |
|                | Glycomine            | Consultant  |         |

|                |                                       |                            |         |
|----------------|---------------------------------------|----------------------------|---------|
|                | Recordati Foundation for Rare Disease | Speaker                    |         |
| Tadafumi Kato  | Sumitomo Pharma Co., Ltd.             | Funding, Speaker           | Speaker |
|                | Otsuka Pharmaceutical Co., Ltd.       | Funding, Speaker           |         |
|                | EA Pharma                             | Speaker                    |         |
|                | Janssen Asia Pacific                  | Writing                    |         |
|                | Eli Lilly Japan K.K.                  | Funding                    |         |
|                | Japan MediPhysics                     | Speaker                    |         |
|                | Yoshitomi Yakuhin                     | Speaker                    |         |
|                | Viartis Pharma                        | Speaker                    |         |
|                | Eisai Co., Ltd.                       | Funding, Speaker           |         |
|                | Lundbeck Japan                        | Speaker                    |         |
|                | Takeda Pharmaceutical Co., Ltd.       | Speaker                    |         |
|                | GlaxoSmithKline                       | Consultant                 |         |
|                | Ono Pharmaceuticals                   | Speaker                    |         |
| Angela Paradis | Biogen                                | Employee and stock holder. | Speaker |
| Wendy Schoop   | Precision BioSciences                 | Employee and stock holder. | Speaker |

*“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”*

These financial relationships with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation.

**All other presenters, planners, editors, or staff report no relationships to disclose:**

*“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”*